Bone Marrow Transplantation News

An oncology financial navigation intervention decreased financial toxicity among patients with blood cancers and their caregivers, according to study results.

The FDA approved omidubicel-onlv, a donor cord blood-based cell therapy, to accelerate neutrophil recovery and reduce the risk for infection among patients with hematologic malignancies undergoing stem cell transplantation.

Reactivation of double-stranded DNA viruses is an important cause of morbidity and mortality after hematopoietic stem cell transplantation.

Miguel-Angel Perales, MD, has been named president of American Society for Transplantation and Cellular Therapy for 2023-2024.

Delaying antibiotic treatment beyond 1 hour from developing neutropenic fever did not affect OS among hospitalized patients with cancer, results from a retrospective study showed.

Time to engraftment after hematopoietic stem cell transplantation is an important outcome that institutions are legally required to report to the Center for International Blood and Marrow Transplant Research.

Pure essential oils can reduce incidence of chemotherapy-induced nausea and vomiting among individuals who undergo bone marrow transplant, according to study results.

Chronic graft-versus-host disease continues to be a leading cause of late morbidity and mortality, complicating approximately 35% to 50% of allogeneic transplantations.

The FDA recently withdrew its emergency use authorization for Evusheld, a combination monoclonal antibody therapy used to prevent COVID-19 among high-risk individuals.

A short course of itacitinib induced high response rates among patients with low-risk acute graft-versus-host disease, according to study results.